Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.
Affiliation
Targeted Therapy Group, Institute of Cancer Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Paterson Institute for Cancer Research, Manchester, UK.Issue Date
2013-09
Metadata
Show full item recordAbstract
The aim of this study was to assess the immunogenic potential of irradiated lymphoma cells in vivo and determine whether immunogenicity can be enhanced by modulation of the host immune system. Syngeneic murine lymphoma models irradiated ex vivo were used as an orthotopic cellular vaccination prior to challenge with viable tumor cells. We demonstrate that irradiated lymphoma cells are poorly immunogenic and that protective anti-tumor CD8 T-cell responses require the addition of immunostimulatory monoclonal antibody as an immune adjuvant, and increased frequency of antigen exposure by multiple vaccinations. Furthermore, we show the potential importance of macrophages in regulating immunogenicity of irradiated lymphoma cells and demonstrate that depletion of macrophages using clodronate-encapsulated liposomes considerably enhances primary vaccination efficacy in the presence of adjuvant anti-CD40 antibody. Our results demonstrate that the immunogenic potential of poorly immunogenic lymphoma cells dying after radiation therapy can be improved by modulation of the host immune system.Citation
Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. 2013, 54 (9):2008-15 Leuk LymphomaJournal
Leukemia & LymphomaDOI
10.3109/10428194.2013.769219PubMed ID
23339450Type
ArticleLanguage
enISSN
1029-2403ae974a485f413a2113503eed53cd6c53
10.3109/10428194.2013.769219
Scopus Count
Collections
Related articles
- Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
- Authors: Carlring J, Szabo MJ, Dickinson R, De Leenheer E, Heath AW
- Issue date: 2012 Mar 1
- Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.
- Authors: Fan Y, Kuai R, Xu Y, Ochyl LJ, Irvine DJ, Moon JJ
- Issue date: 2017 Dec 13
- In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
- Authors: Oba T, Makino K, Kajihara R, Yokoi T, Araki R, Abe M, Minderman H, Chang AE, Odunsi K, Ito F
- Issue date: 2021 May
- CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
- Authors: Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, Sondel PM
- Issue date: 2008 Aug
- Three steps to breaking immune tolerance to lymphoma: a microparticle approach.
- Authors: Makkouk A, Joshi VB, Lemke CD, Wongrakpanich A, Olivier AK, Blackwell SE, Salem AK, Weiner GJ
- Issue date: 2015 Apr